NRC — Preclinical in vivo facility

For biotechnology and life sciences companies moving a biologic or vaccine toward clinical development, generating strong preclinical evidence can be one of the most complex and costly steps. The NRC — Preclinical in vivo facility offers Canadian companies access to specialized expertise and advanced infrastructure to evaluate safety, efficacy, and performance before entering human trials. Delivered by the National Research Council of Canada, this national, fee‑for‑service facility supports businesses that need high‑quality in vivo data to de‑risk their development programs.

Through the NRC’s Human Health Therapeutics Research Centre, clients can work with multidisciplinary teams experienced in biologics and vaccine development across infectious disease, cancer, inflammatory conditions, and CNS disorders. The facility supports everything from therapeutic target and biomarker validation to pharmacokinetics, immune response analysis, and efficacy testing in established and custom animal models. Advanced imaging capabilities and regulated animal care standards help ensure that data generated is suitable for regulatory preparation, including early groundwork for IND submissions.

This program is well suited for SMEs and larger enterprises that want to accelerate development without building in‑house preclinical infrastructure. Because support is delivered through specialized services rather than fixed grants, project scope and costs vary based on individual needs. Businesses interested in understanding how this facility could support their pipeline will want to explore the full details to see how it aligns with their next development milestone.